# Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy

> **NCT05251493** · PHASE3 · RECRUITING · sponsor: **Saskatchewan Health Authority - Regina Area** · enrollment: 280 (estimated)

## Conditions studied

- Iron Deficiency Anaemia in Childbirth

## Interventions

- **DRUG:** Iron Isomaltoside 1000, ferric derisomaltose
- **DRUG:** Iron sucrose

## Key facts

- **NCT ID:** NCT05251493
- **Lead sponsor:** Saskatchewan Health Authority - Regina Area
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-06
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-02-28
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05251493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05251493, "Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05251493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*